Multiple Myeloma Support + Trials

What's the purpose of this trial?

The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

This is an upcoming trial that has not yet started accepting patients.

What will happen during the trial?

This trial is anticipated to open to US patients in April 2023

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

Inclusion Criteria:

Have a diagnosis of multiple myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteria
Be newly diagnosed and not considered a candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT) due to: ineligible due to advanced age OR; ineligible due to the presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT OR; deferral of high-dose chemotherapy with ASCT as initial treatment
Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
A female participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 3 months after the last dose of study treatment
A male participant must agree not to plan to father a child while enrolled in this study or within 3 months after the last dose of study treatment

Exclusion Criteria:

Received a cumulative dose of systemic corticosteroids equivalent to greater than or equal to (>=) 20 milligrams (mg) of dexamethasone within 14 days before randomization
Had plasmapheresis within 28 days of randomization
Had a stroke, transient ischemic attack, or seizure within 6 months prior to randomization
Known allergies, hypersensitivity, or intolerance to teclistamab excipients
Known contraindications to the use of daratumumab or lenalidomide per local prescribing information

Additional Trial Information

Phase 3

Enrollment: 1,030 patients (estimated)

Need Help?

Interested in joining or learning more about this trial?

(888) 828-2206

Interested in this trial?

Call us today 😀

We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.
(888) 828-2206

Add this trial to your favorites

If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

Find a nearby location

You can explore trial locations from around the US and connect directly with a trial coordinator.
Find Nearby Locations

Talk to your doctor

You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

What's the purpose of this trial?

What will happen during the trial?

You may be able to join this trial if you:

Additional Trial Information

Trial Locations

All Trial Locations

California

Not Yet Accepting

Louisiana

Not Yet Accepting

Massachusetts

Not Yet Accepting

Michigan

Not Yet Accepting

Not Yet Accepting

New Jersey

Not Yet Accepting

New York

Not Yet Accepting

North Carolina

Not Yet Accepting

Not Yet Accepting

Not Yet Accepting

Ohio

Not Yet Accepting

Oregon

Not Yet Accepting

Pennsylvania

Not Yet Accepting

Texas

Not Yet Accepting

Virginia

Not Yet Accepting

Washington

Not Yet Accepting

Washington, D.C.

Not Yet Accepting